The research section is for readers who want to know what the evidence actually says, not just what the headlines suggest. It brings trials, regulator updates, real-world studies and terminology pages into one place, with UK meaning kept separate from U.S. momentum and future-market speculation.
The strongest starting point is the oral GLP-1 evidence library, which pulls together the main study families, key UK safety updates and the source material behind the site's current-status wording.
Open the evidence libraryA visual source register covering the main items that shape the current oral GLP-1 conversation: UK real-world oral semaglutide data, OASIS trials, PIONEER trials, ATTAIN and ACHIEVE orforglipron evidence, FDA approval context and MHRA safety updates.
People searching GLP-1 tablets often encounter a muddle of product names, trial numbers and country-specific news. This hub is meant to separate those layers: what was studied, what was approved, what is current in the UK and what is still future-facing.
Clinical and status claims are tied to named sources, not repeated as loose marketing language.
The same fact can mean something different in the UK, the U.S. or a trial setting. That context is part of the evidence, not an afterthought.
The aim is not to stockpile links. It is to help readers understand what a study or approval does and does not change.
The research section now includes study-family explainers, claim checking, a terminology glossary, a UK-vs-U.S. status checker and trust pages. Together, they aim to answer the questions that ordinary search results usually leave blurred.
The research section is anchored to regulator and peer-reviewed sources before interpretation is added. These sources establish the first version of the evidence library and keep UK safety, US approval and clinical trial evidence apart.
| Source | Used for | Why it matters |
|---|---|---|
| PIONEER REAL UK | UK real-world oral semaglutide evidence | Gives the site a UK-specific evidence anchor for Rybelsus in routine diabetes care. |
| OASIS 1 and OASIS 4 | Higher-dose oral semaglutide obesity trials | Explains why oral weight-loss tablet headlines are clinically important while still separate from current UK access. |
| ATTAIN-1 and ACHIEVE-1 | Orforglipron trial evidence | Shows why Foundayo/orforglipron matters as a major oral GLP-1 development. |
| FDA Foundayo approval | US regulatory status | Supports US approval claims without turning them into UK availability claims. |
| MHRA February 2026 safety roundup | UK semaglutide safety context | Keeps safety updates visible beside effectiveness evidence. |